Cannabinoid | Moderate Risk

Nabiximols (THC:CBD Oromucosal Spray) (Sativex)

Nabiximols (THC:CBD Oromucosal Spray) risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Sativex.

Source: AllMeds_Curated Updated April 2026

Nabiximols (THC:CBD Oromucosal Spray) (brand names: Sativex) is classified as Moderate risk (5 risk points) by AllMeds. It is a S8 medication under the TGA in Australia. TGA registered for MS spasticity

Key Takeaways

  • TGA Schedule: S8 in Australia
  • Risk level: Moderate (5 points)

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S8 Not PBS listed

Risk Profile

Risk Level Moderate
Risk Points 5
CNS Depressant No
Respiratory Risk No

TGA registered for MS spasticity

Regulatory and Compliance Guidance

When Nabiximols (THC:CBD Oromucosal Spray) appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.

Australia TGA / PBS / State Schemes

Classified as S8 under the Therapeutic Goods Administration (TGA).

Clinical Evidence

  • MHRA Approval: Sativex for MS Spasticity (UK) - MHRA (2010)

    First cannabis-based medicine approved in the UK. Licensed for MS spasticity not adequately responding to other medications.

    UK regulatory approval

  • ARTG Registration: Sativex (nabiximols) - TGA (2013)

    Sativex (nabiximols) is TGA-registered for MS spasticity. THC:CBD 1:1 oromucosal spray. S8.

    Full TGA registration

Need to assess this medication across your caseload?

Run a full risk assessment including Nabiximols (THC:CBD Oromucosal Spray) interactions and compliance checks.

AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.

No credit card required. No signup for your first 2 questions.

Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.